Maggie C.U. Cheang

TL;DR: D diagnosis by intrinsic subtype adds significant prognostic and predictive information to standard parameters for patients with breast cancer.

TL;DR: Basal-like breast tumors occurred at a higher prevalence among premenopausal African American patients compared with postmenopausal American and non-African American patients in this population-based study, and their associations with tumor size, axillary nodal status, mitotic index, nuclear pleomorphism, combined grade, p53 mutation status, and breast cancer-specific survival were examined.

TL;DR: A panel of four antibodies (ER, HER1, HER2, and cytokeratin 5/6) can accurately identify basal-like tumors using standard available clinical tools and shows high specificity.

TL;DR: Luminal B and luminal–HER2-positive breast cancers were statistically significantly associated with poor breast cancer recurrence-free and disease-specific survival in all adjuvant systemic treatment categories.

TL;DR: Breast cancer subtypes are associated with distinct patterns of metastatic spread with notable differences in survival after relapse, and luminal/HER2 and HER2-enriched tumors were associated with a significantly higher rate of brain, liver, and lung metastases.